Cellular Oncology

SEP 29, 2026 · JOURNAL ARTICLE

BRD4 is a key regulator of STING expression

Cellular Oncology

The bromodomain and extra-terminal (BET) protein family, especially the bromodomain-containing protein 4 (BRD4), drives tumor progression. BET inhibitors (BETi) have shown therapeu

SEP 25, 2026 · JOURNAL ARTICLE

Ophiobolin derivative DM28 enhances immunoradiotherapy response via regulating SLC3A2-associated ferroptosis in non-small cell lung cancer

Cellular Oncology

Immunoradiotherapy substantially improves the efficacy of non-small cell lung cancer (NSCLC) patients, but the response rate is only 40–60%. MHO7 (6-epi-ophiobolin G) from mangrove

SEP 23, 2026 · JOURNAL ARTICLE

Adaptive evolution of cancer-associated extrachromosomal DNA under therapeutic pressure: origin attribution, structural remodeling, mechanisms of acquired resistance, and therapeutic implications

Cellular Oncology

Cancer-associated extrachromosomal DNA (ecDNA) increases intratumoral heterogeneity through non-Mendelian inheritance, high-copy-number oncogene amplification, and structural plast

SEP 19, 2026 · JOURNAL ARTICLE

ATG4 targeting peptide inhibits autophagy and elevates reactive oxygen species to trigger cancer cell death

Cellular Oncology

ATG4, an autophagy protease, cleaves ATG8 family proteins to activate autophagy, a process linked to cancer progression. This study aimed to design α-helical peptides targeting ATG

AUG 13, 2026 · JOURNAL ARTICLE

Neural regulation of cancer: from microenvironmental hijacking to systemic circuit co-option

Cellular Oncology

A narrative review proposing a conceptual framework for neuro-tumor interactions without reporting primary experimental data, effect sizes, or comparative evidence.